A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease
A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Inclusion Criteria:
Exclusion Criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
New York, New York 10021-5663, United States
Campinas, 13060-904, Brazil
Vitória, 29040-091, Brazil
Bergamo, 24127, Italy
Milan, 20154, Italy
Kashiwa-shi, 277-0871, Japan
Setagaya Ku, 157 8535, Japan
Nordbyhagen, 1474, Norway